Research programme: mitochondria-derived peptides - CohBar

Drug Profile

Research programme: mitochondria-derived peptides - CohBar

Alternative Names: CB-4209; CB-4211; Humanin - CohBar; MBTs - CohBar; MDPs - CohBar; Mitochondria-based therapeutics - CohBar; MOTS-c; SHLP 2; SHLP 6; Small humanin-like peptides - CohBar

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Albert Einstein College of Medicine; University of Southern California
  • Developer Albert Einstein College of Medicine; CohBar; University of Southern California
  • Class Hormones; Peptides
  • Mechanism of Action AMP activated protein kinase stimulants; Angiogenesis inhibitors; Apoptosis stimulants; Glucose stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Non-alcoholic steatohepatitis; Obesity; Prostate cancer; Type 2 diabetes mellitus
  • Research Alzheimer's disease; Atherosclerosis; Cancer; Cerebral ischaemia; Myocardial ischaemia; Neurodegenerative disorders

Most Recent Events

  • 23 Nov 2017 Pharmacodynamics data from a preclinical studies in Nonalcoholic Steatohepatitis and Obesity presented at the at 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD- 2017)
  • 23 Oct 2017 Pharmacodynamic data from preclinical studies in Non-alcoholic steatohepatitis released by CohBar
  • 10 Jan 2017 Preclinical trials in Nonalcoholic steatohepatitis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top